Phase 2 Leukaemia Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with acute myeloid leukemia (a type of blood cancer) confirmed by a laboratory test, who have not yet received treatment, and who are unable or unwilling to receive the standard chemotherapy combination (cytarabine and anthracycline) due to age, other health conditions, or personal preference
• People aged 60 years or older, of any gender, with an expected survival of more than 3 months
• People whose kidneys are functioning well enough, with a kidney filtration rate of at least 30 mL/min
• People whose liver enzyme levels (AST and ALT) and bilirubin are within acceptable ranges, unless any abnormality is caused by the leukemia itself (confirm with trial site)
• People with a functional status score of 2 or less on the ECOG scale, meaning they are able to care for themselves even if they are not able to do heavy physical work (confirm with trial site)
• People who are able to understand the trial and are willing to give their informed consent to participate

Who may not be able to join:

• People diagnosed with a specific subtype of leukemia called acute promyelocytic leukemia (APL), or whose leukemia has certain low-risk genetic features (t(8;21), inv(16), or t(16;16))
• People whose leukemia has spread to the central nervous system (brain and spinal cord) and is currently active
• People with a history of certain bone marrow or blood disorders, including myelofibrosis, essential thrombocythemia, polycythemia vera, or chronic myelogenous leukemia (CML), or a form of leukemia linked to a specific gene change called BCR-ABL1
• People who are HIV-positive, or who have an active hepatitis B or hepatitis C infection confirmed by blood tests
• People with serious ongoing conditions affecting the lungs (requiring continuous oxygen), kidneys, nervous system, mental health, hormonal system, immune system, liver, or heart
• People with a condition that prevents them from absorbing medication taken by mouth, or any other condition that makes oral medication unsuitable
• People with certain significant heart problems, including a notably prolonged QTc interval on a heart tracing (over 450 ms in men or 470 ms in women), irregular heart rhythms, a partial heart block, a heart attack, or heart failure within the past year, or coronary heart disease currently requiring medication
• People with a serious infection that is currently active and not under control
• People who have had another type of cancer within the past 2 years, with exceptions for certain early-stage or skin cancers that have been adequately treated (confirm with trial site)
• People whose white blood cell count is above 25 x 10⁹/L, unless it has been reduced to an acceptable level through medication or a blood-filtering procedure
• People with a mental health condition that would prevent safe participation in the trial
• People who have previously received certain treatments, including hypomethylating agents, venetoclax, chemotherapy for a condition called myelodysplastic syndrome (MDS), or a solid organ transplant
• People whom the trial investigators consider unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.